Attached files
| file | filename |
|---|---|
| EX-31.1 - EXHIBIT 31.1 - IMMUNE PHARMACEUTICALS INC | v434974_ex31-1.htm |
| 10-K - 10-K - IMMUNE PHARMACEUTICALS INC | v434974_10k.htm |
| EX-23.1 - EXHIBIT 23.1 - IMMUNE PHARMACEUTICALS INC | v434974_ex23-1.htm |
| EX-32.1 - EXHIBIT 32.1 - IMMUNE PHARMACEUTICALS INC | v434974_ex32-1.htm |
| EX-32.2 - EXHIBIT 32.2 - IMMUNE PHARMACEUTICALS INC | v434974_ex32-2.htm |
| EX-31.2 - EXHIBIT 31.2 - IMMUNE PHARMACEUTICALS INC | v434974_ex31-2.htm |
| EX-21.1 - EXHIBIT 21.1 - IMMUNE PHARMACEUTICALS INC | v434974_ex21-1.htm |
| EX-10.44 - EXHIBIT 10.44 - IMMUNE PHARMACEUTICALS INC | v434974_ex10-44.htm |
| EX-10.45 - EXHIBIT 10.45 - IMMUNE PHARMACEUTICALS INC | v434974_ex10-45.htm |
Exhibit 23.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statements of Immune Pharmaceuticals, Inc. on Form S-8 (Nos. 333-198521, 333-156438, 333-151150, 333-130865, 333-130861 and 333-130860) and Form S-3 (Nos. 333-198309 and 333-198647) of our report dated April 15, 2015, on our audit of the consolidated financial statements as of December 31, 2014 and for the year then ended, which report is included in this Annual Report on Form 10-K to be filed on or about March 30, 2016.
/s/ EisnerAmper LLP
Iselin, New Jersey
March 30, 2016